Antifungal effect of voriconazole on intracellular Candida glabrata, Candida krusei and Candida parapsilosis in human monocyte-derived macrophages

Journal of Medical Microbiology

Volumn 55, Issue 7, 2006, Pages 865-870

  Bopp, Lawrence H ^a   Baltch, Aldona L ^a,b   Ritz, William J ^a,b   Michelsen, Phyllis B ^a,b   Smith, Raymond P ^a,b  

^a STRATTON VA MEDICAL CENTER   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CELL LYSATE; CONTROLLED STUDY; DRUG EFFECT; DRUG SENSITIVITY; FUNGUS GROWTH; HUMAN; HUMAN CELL; MACROPHAGE; MINIMUM INHIBITORY CONCENTRATION; PHAGOCYTOSIS; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; COLONY COUNT, MICROBIAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, FUNGAL; HUMANS; MACROPHAGES; PYRIMIDINES; TRIAZOLES;

EID: 33745639702     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/jmm.0.46393-0     Document Type: Article

References (22)

1. Anaissie, E. J., Rex, J. H., Uzun, O. & Vartivarian, S. (1998). Predictors of adverse outcome in cancer patients with candidemia. Am J Med 104, 238-245.
2. Baltch, A. L., Smith, R. P., Franke, M. A., Ritz, W. J., Michelsen, P. B. & Bopp, L. H. (2001). Effects of cytokines and fluconazole on the activity of human monocytes against Candida albicans. Antimicrob Agents Chemother 45, 96-104.
3. Baltch, A. L., Smith, R. P., Ritz, W. J., Bopp, L. H. & Michelsen, P. B. (2005). Intracellular activity of voriconazole, fluconazole, and itraconazole against Candida albicans in human monocytes with and without activation by GM-CSF and TNP-α. J Appl Res 5, 543-552.
4. Bodey, G. P., Mardani, M., Hanna, H. A., Boktour, M., Abbas, J., Girgawy, E., Hachem, R. Y., Kontoyiannis, D. P. & Raad, I. I. (2002). The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. Am J Med 112, 380-385.
5. Draper, N. & Smith, H. (1981a). Applied Regression Analysis, 2nd edn, p. 512. New York: Wiley.
6. Draper, N. & Smith, H. (1981b). Applied Regression Analysis, 2nd edn, pp. 85-96. New York: Wiley.
7. Ghannoum, M. A., Fu, Y., Ibrahim, A. S., Mortara, L. A., Shafiq, M. C., Edward, J. E., Jr & Criddle, R. S. (1995). In vitro determination of optimal antifungal combinations against Cryptococcus neoformans and Candida albicans. Antimicrob Agents Chemother 39, 2459-2465.
8. Girmenia, C., Venditti, M. & Martino, P. (2003). Fluconazole in combination with flucytosine in the treatment of fluconazole-resistant Candida infections. Diagn Microbiol Infect Dis 46, 227-231.
9. Loeffler, J. & Stevens, D. A. (2003). Antifungal drug resistance. Clin Infect Dis 36 (supplement I), S31-S41.
10. Maródi, L., Korchak, H. M. & Johnston, R. B., Jr (1991a). Mechanisms of host defense against Candida species. 1. Phagocytosis by monocytcs and monocyte-derived macrophages. J Immunol 146, 2783-2789.
11. Maródi, L., Forehand, J. R. & Johnston, R. B., Jr (1991b). Mechanisms of host defense against Candida species. 2. Biochemical basis for the killing of Candida by mononuclear phagocytes. J Immunol 146, 2790-2794.
12. McNeil, M. M., Nash, S. L., Hajjeh, R. A., Phelan, M. A., Conn, L. A., Plikaytis, B. D. & Warnock, D. W. (2001). Trends in mortality due to invasive mycotic disease in the United States, 1980-1997. Clin Infect Dis 33, 641-647.
13. Mukhergee, P. K., Sheehan, D. J., Hitchcock, C. A. & Ghannoum, M. A. (2005). Combination treatment of invasive fungal infections. Clin Microbiol Rev 18, 163-194.
14. National Committee for Clinical Laboratory Standards (2002). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. Approved standard. NCCLS document M27-A2. Wayne, PA: National Committee for Clinical Laboratory Standards.
15. Ostrofsky-Zeichner, L., Rex, R. H., Pappas, P. G. & 9 other authors (2003). Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 47, 3149-3154.
16. Pasqual, A., Garcia, I., Conejo, C. & Perea, E. P. (1993). Uptake and intracellular activity of fluconazole in human polymorphonuclear leukocytes. Antimicrob Agents Chemother 37, 187-190.
17. Pfaller, M. A., Diekema, D. J., Jones, R. N., Messer, S. A., Hollis, R. J. & the Sentry Participants Group (2002). Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997-2000. J Clin Microbiol 40, 852-856.
18. Sanati, H., Belanger, P., Fratti, R. & Ghannoum, M. (1997). A new triazole, voriconazole (UK 109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei. Antimicrob Agents Chemother 41, 2492-2496.
19. Sheehan, D. J., Hitchcock, C. A. & Sibley, C. M. (1999). Current and emerging azole antifungal agents. Clin Microbiol Rev 12, 40-79.
20. Stuart, A. & Ord, J. K. (1991a). Kendall's Advanced Theory of Statistics, vol. 2, pp. 1101-1153. New York: Oxford University Press.
21. Stuart, A. & Ord, J. K. (1991b). Kendall's Advanced Theory of Statistics, vol. 2, p. 1149, section 29.58. New York: Oxford University Press.
22. Vora, S., Purimetla, N. & Brummer, E. (1998). Activity of voriconazole, a new triazole, combined with neutrophils and monocytes against Candida albicans: effect of G-CSF and GM-CSF. Antimicrob Agents Chemother 42, 907-910.